Trial Profile
A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Carcinoma; Early breast cancer; Inflammatory breast cancer
- Focus Therapeutic Use
- 10 Jul 2023 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 10 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 30 Jun 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.